Redmile Group, LLC Immatics N.V. Transaction History

Redmile Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.0 - $9.37 $1.65 Million - $2.58 Million	-275,339 Reduced 37.98%	449,661 $3.92 Million
Q1 2022 May 16, 2022	SELL	$6.64 - $12.85 $6.91 Million - $13.4 Million	-1,040,692 Reduced 58.94%	725,000 $5.79 Million
Q4 2021 Feb 14, 2022	SELL	$10.81 - $14.38 $1.9 Million - $2.53 Million	-176,200 Reduced 9.07%	1,765,692 $23.7 Million
Q2 2021 Aug 16, 2021	SELL	$10.43 - $12.81 $1.47 Million - $1.81 Million	-140,922 Reduced 6.77%	1,941,892 $22.5 Million
Q1 2021 May 17, 2021	BUY	$10.24 - $14.6 $148,613 - $211,889	14,513 Added 0.7%	2,082,814 $23.3 Million
Q4 2020 Feb 16, 2021	SELL	$9.67 - $12.05 $596,629 - $743,472	-61,699 Reduced 2.9%	2,068,301 $22.3 Million
Q3 2020 Nov 16, 2020	BUY	$8.73 - $15.15 $18.6 Million - $32.3 Million	2,130,000 New	2,130,000 $22.6 Million

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.